Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01)
- 20 December 2020
- journal article
- Published by Japan Lung Cancer Society in Haigan
- Vol. 60 (7), 966-971
- https://doi.org/10.2482/haigan.60.966
Abstract
目的.局所進行非小細胞肺癌患者に対しデュルバルマブが用いられるようになったが,どの程度非投与患者がいるのか明確でなく,投与割合を調査し,投与回避理由を調査した.研究計画.肺癌治療専門医がいる12施設のデータを後方視的に評価した.2018年5月から2019年12月に治療された局所進行非小細胞肺癌患者を対象とした.デュルバルマブの投与群と非投与群で患者背景を比較し,非投与理由を質問票で確認した.結果.199人が化学放射線療法を施行され,169人(84.9%)にデュルバルマブが投与された.年齢中央値が非投与群で有意に高く(70歳 vs 67歳,p=0.0465),PS≧1の患者が非投与群で有意に多かった(65.5% vs 40.4%,p=0.0148).質問票により確認された非投与理由は,「化学放射線療法の副作用」7例,「患者希望」5例,「腫瘍進行」4例,「PS低下」「遺伝子変異陽性」3例,「自己免疫疾患の合併」2例であった.結論.デュルバルマブは84.9%の患者に投与され,投与回避要因として,年齢,PS,化学放射線療法の有害事象,遺伝子変異などがあった.This publication has 11 references indexed in Scilit:
- Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussionESMO Open, 2019
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCThe New England Journal of Medicine, 2018
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410JNCI Journal of the National Cancer Institute, 2011
- Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105Journal of Clinical Oncology, 2010
- Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: OLCSG 0007Journal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non–Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 TrialJNCI Journal of the National Cancer Institute, 1996
- Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1995